Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
4.69
Oct 30 • 3:59 PM ET Dollar change+0.34 Percentage change(7.82%)
Aftermarket Close
4.61
Aftermarket • 7:30 PM ET Dollar change-0.08 Percentage change(-1.70%)
Index
-
Market Cap
70.27M
Enterprise Value
70.79M
Income
-10.92M
Sales
31.27M
Book/sh
1.16
Cash/sh
0.26
Employees
93
IPO
Aug 11, 2009
P/E
-
Forward P/E
-
PEG
-
P/S
2.25
P/B
4.03
P/C
18.20
P/FCF
103.34
EV/EBITDA
-
EV/Sales
2.26
Quick Ratio
0.96
Current Ratio
0.96
Debt/Eq
0.27
LT Debt/Eq
0.24
Option/Short
Yes / Yes
EPS (ttm)
-0.73
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
20.68% 2.82%
Sales past 3/5Y
1.95% 3.52%
EPS Y/Y TTM
-244.92%
Sales Y/Y TTM
-25.68%
EPS Q/Q
-476.57%
Sales Q/Q
-98.46%
Insider Own
41.60%
Insider Trans
0.00%
Inst Own
16.57%
Inst Trans
-6.57%
ROA
-14.91%
ROE
-42.92%
ROIC
-50.43%
Gross Margin
86.22%
Oper. Margin
-29.58%
Profit Margin
-34.92%
SMA20
-30.27%
SMA50
-34.16%
SMA200
-2.32%
Trades
Shs Outstand
14.98M
Shs Float
8.75M
52W High
9.28 -49.46%
52W Low
1.43 226.92%
Volatility
28.81% 13.32%
ATR (14)
0.81
RSI (14)
35.36
Beta
0.10
Rel Volume
1.53
Avg Volume
84.14K
Volume
128,962
Perf Week
-44.76%
Perf Month
-37.55%
Perf Quarter
-34.68%
Perf Half Y
38.72%
Perf YTD
51.96%
Perf Year
88.41%
Perf 3Y
208.58%
Perf 5Y
124.84%
Perf 10Y
26.00%
Prev Close
4.35
Price
4.69
Change %
7.82%
Consensus
Strong Buy
Avg. Price Target
$9.75
Implied Upside
+107.9%
Analysts3incl. previous ratings
Rating Distribution1 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 12, 2012Reiterated
UBS logoUUBS
Neutral$6.50 → $5+6.6%
Feb 01, 2011Reiterated
UBS logoUUBS
Neutral$8 → $6.50+38.6%
Dec 16, 2010Downgrade
UBS logoUUBS
Buy → Neutral$10 → $8+70.6%
Aug 17, 2010Reiterated
UBS logoUUBS
Buy$11 → $10+113.2%
Aug 17, 2010Reiterated
MMorgan Joseph
Buy$15 → $10+113.2%
Aug 17, 2010Downgrade
JEF logoJJefferies
Buy → Hold$13 → $5.50+17.3%
May 14, 2010Reiterated
MMorgan Joseph
Buy$21 → $15+219.8%
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. It operates through the following geographical segments: China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The firm products include Acetadote, Caldolor, Kristalose, Vaprisol, Talicia, Vibativ, Sancuso, Omeclamox, RediTrex, and Other. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.
FounderMr. A. J. Kazimi MBA
Vice President Accounting & Finance and CFOMr. John Michael Hamm C.M.A.
Vice President of Organizational DevelopmentMr. Todd M. Anthony
Managing Director of Banking & Investor RelationsMr. Adam S. Mostafa